OncoZenge AB (publ) announced that ongoing stability studies for the revised formulation of BupiZenge(TM) show positive results. stability studies of BupiZenge (TM) are ongoing in line with previous communication from the company. The data now obtained shows 3 months of positive results within the desired limits of the specification for the development of the latest formulation.

This data complements earlier data and analyzes and confirms the flexibility that OncoZenge now possesses to take BupiZenge to the next clinical development phase and market approval, with different packaging options.